329: Lilly's earnings surprise, investors mull the election, & a spooky ghost story

This week features a lively mix of Halloween fun and biotech chat. The hosts share their favorite candies while diving into Eli Lilly and Pfizer's surprising earnings reports. They explore how a Trump or Harris presidency might reshape healthcare and what it means for the biopharma sector. The conversation blends serious insights with playful banter, wrapping up with a spooky ghost story that adds a festive flair. Expect humor, ghostly tales, and sharp analysis on the industry's future!